GlassScriptPhysician profile
Stephen Macenas
NPI 1871133538
$2,659.74
in general payments reported to CMS, 2019-2025
25 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.02 · 2023: $172 · 2024: $1,208 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,628.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $537.60 | 2024 | Axonics |
| Novo Nordisk INC | $272.61 | 2025 | Ozempic |
| Antares Pharma, INC. | $220.51 | 2024-2025 | Xyosted |
| Endo USA, INC. | $206.66 | 2024-2025 | Xiaflex, Aveed |
| 180 Medical, INC. | $192.57 | 2024-2025 | |
| Procept Biorobotics Corporation | $186.86 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Agiliti Surgical, INC. | $161.51 | 2024-2025 | Cyberblade, Quanta Litho, Koelis Trinity Mri/US Fusion |
| Progenics Pharmaceuticals, INC. | $158.10 | 2025 | |
| Abbott Laboratories | $132.10 | 2024 | Proclaim |
| Olympus America INC. | $85.09 | 2024-2025 | Itind System, Oes Cystonephrofiberscope, Cysto-Nephro Videoscope |
| Ferring Pharmaceuticals INC. | $79.66 | 2024-2025 | Adstiladrin |
| Abbvie INC. | $55.67 | 2024-2025 | |
| Boston Scientific Corporation | $52.30 | 2023-2025 | Rezum Generator, Axonics, Solyx Sis System |
| Coloplast Corp | $41.57 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.57 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $36.40 | 2023-2024 | Xiaflex |
| Tolmar, INC. | $32.84 | 2025 | Jatenzo |
| Convatec INC. | $27.39 | 2025 | |
| Mimedx Group, INC. | $27.28 | 2025 | |
| Telix Pharmaceuticals | $23.43 | 2024 | Illuccix |
| Urogen Pharma, INC. | $22.78 | 2024 | |
| Pfizer INC. | $19.55 | 2025 | |
| Halozyme INC | $18.67 | 2023 | |
| Phadia US INC. | $15.88 | 2022 | |
| Cranial Technologies, INC | $15.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Macenas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.